Description

Medtronic’s 139% U.S. Ablation Growth — Can Sphere-9 Keep Taking Share?

Medtronic plc reported a robust start to fiscal year 2027 with first-quarter revenue reaching $9.8 billion, reflecting a 13.7% organic growth rate and adjusted earnings per share (EPS) of $1.45, both surpassing consensus expectations. This growth was broad-based across multiple business segments, geographic regions, and product lines, supported by an additional selling week contributing approximately $570 million to revenue. The company emphasized strength in its three largest operating units: Cardiac Rhythm Management (CRM), Cranial & Spinal Technologies (CST), and Surgical, which all posted solid results. Within cardiovascular, the Cardiac Ablation Solutions (CAS) segment notably drove growth with an 88% increase, particularly strong in the U.S. at 139%. CAS remains in early stages of market penetration but achieved significant U.S. share gains with its Sphere-9 platform surpassing $2 billion in trailing twelve-month revenue. CRM experienced 15% global growth, supported by sustained innovation including Micra and conduction system pacing.